Low-dose ladostigil for mild cognitive impairment | Zendy

Lon S. Schneider | Zendy; Yona Geffen | Zendy; Jonathan Rabinowitz | Zendy; Ronald G. Thomas | Zendy; Reinhold Schmidt | Zendy; Stefan Ropele | Zendy; Marta Weinstock | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Low-dose ladostigil for mild cognitive impairment

Author(s) -

Lon S. Schneider,

Yona Geffen,

Jonathan Rabinowitz,

Ronald G. Thomas,

Reinhold Schmidt,

Stefan Ropele,

Marta Weinstock

Publication year - 2019

Publication title -

neurology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.91

H-Index - 364

eISSN - 1526-632X

pISSN - 0028-3878

DOI - 10.1212/wnl.0000000000008239

Subject(s) - clinical dementia rating , placebo , geriatric depression scale , medicine , dementia , wechsler memory scale , alzheimer's disease , hippocampus , temporal lobe , atrophy , psychology , wechsler adult intelligence scale , psychiatry , cognition , disease , pathology , depressive symptoms , alternative medicine , epilepsy

Ladostigil reduces oxidative stress and microglial activation in aging rats. We assessed its safety and potential efficacy in a 3-year, randomized, double-blind, placebo-controlled phase 2 clinical trial in patients with mild cognitive impairment (MCI) and medial temporal lobe atrophy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research